Advertisement

Topics

New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

07:00 EST 3 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA® in the Treatment of Moderate to Severe Plaque Psoriasis Janssen Research & Development, LLC ...

Other Sources for this Article

Media Contacts:
Brian Kenney
Office: +1 215 628 7010
Mobile: +1 215 620 0111
or
Emily Bone
Mobile: +44 7876 394360
ebone1@its.jnj.com
or
Investor Contacts:
Johnson & Johnson
Joseph J. Wolk
Office: +1 732 524 1142
or
Lesley Fishman
Office: +1 732 524 3922

NEXT ARTICLE

More From BioPortfolio on "New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...